Skip to main content
main-content

01.12.2014 | Case Report | Ausgabe 1/2014 Open Access

Clinical Sarcoma Research 1/2014

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series

Zeitschrift:
Clinical Sarcoma Research > Ausgabe 1/2014
Autoren:
Arie J Verschoor, Hans Gelderblom
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​2045-3329-4-14) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AJV participated in the collection of the data and the literature search and drafted the manuscript. HG participated in the design of the study and corrected the manuscript. Both authors have read and approved the final manuscript.

Abstract

Background

Recently, the phase III PALETTE study introduced pazopanib (Votrient®) as treatment for adult patients with locally advanced or metastatic non-liposarcoma soft tissue sarcoma after prior treatment with doxorubicin and/or ifosfamide. Pneumothorax was reported as adverse event in 8 of 246 treated patients (3.3%) in that study. This case series presents the incidence and clinic of this complication in the Leiden University Medical Centre.

Cases

Forty-three patients were treated with pazopanib of which six patients (14.0%) developed a pneumothorax. These six patients were treated for malignant peripheral nerve sheath tumour, angiosarcoma, synovial sarcoma, fibromyxomatoid sarcoma, pleomorphic sarcoma and endometrial stromal sarcoma. All six patients had subpleural pulmonary or pleural metastases at the start of pazopanib and the pneumothorax developed during or shortly after treatment with pazopanib and was difficult to treat.

Discussion

The incidence reported by us is higher than the incidence in the PALETTE study. Trials with pazopanib in renal cell carcinoma, urothelial carcinoma and cervix carcinoma did not report pneumothorax as an adverse event, suggesting pneumothorax as a specific adverse event in soft tissue sarcoma patients treated with pazopanib. This may be related to the fact that there is often pleural metastatic involvement and cystic degeneration due to pazopanib treatment may add to the risk.

Conclusion

The risk of an, often difficult to treat, pneumothorax during pazopanib therapy should be discussed with the patient before initiation of treatment for a pulmonary metastasized sarcoma and physicians should be alert to the occurrence of such an event.
Zusatzmaterial
Authors’ original file for figure 1
13569_2014_63_MOESM1_ESM.tif
Authors’ original file for figure 2
13569_2014_63_MOESM2_ESM.tif
Authors’ original file for figure 3
13569_2014_63_MOESM3_ESM.tif
Authors’ original file for figure 4
13569_2014_63_MOESM4_ESM.tif
Authors’ original file for figure 5
13569_2014_63_MOESM5_ESM.jpg
Authors’ original file for figure 6
13569_2014_63_MOESM6_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Clinical Sarcoma Research 1/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise